FDA Introduces Agentic AI Platform for Staff Workflows

The U.S. Food and Drug Administration (FDA) has introduced an agentic artificial intelligence platform designed to assist employees with complex, multistep tasks. Staff can use the system for meeting management, pre-market and post-market reviews, surveillance, inspections, and administrative functions.

The agency described the rollout as exploratory and confirmed that the system will not make regulatory decisions or replace human judgment. The AI operates within a high-security GovCloud environment and does not train on data submitted by regulated industries, ensuring confidentiality of sensitive information.

Agentic AI models are built to pursue defined goals through coordinated actions between components, with human oversight guiding the final outputs. The FDA’s staff have been invited to test and build solutions using the system over the next two months, with demonstrations planned for a Scientific Computing Day in January.

This initiative follows the earlier release of the FDA’s generative AI model, Elsa, which has been voluntarily adopted by more than 70% of the agency’s workforce. The new agentic platform expands the agency’s use of artificial intelligence as it seeks to improve efficiency in regulatory and scientific workflows.